95 related articles for article (PubMed ID: 6489764)
1. A long-term study with co-dergocrine mesylate (Hydergine) in healthy pensioners. Results after 3 years.
Köberle S; Spiegel R
Gerontology; 1984; 30 Suppl 1():3-52. PubMed ID: 6489764
[TBL] [Abstract][Full Text] [Related]
2. Effects of intravenous high dose co-dergocrine mesylate ('Hydergine') in elderly patients with severe multi-infarct dementia: a double-blind, placebo-controlled trial.
Arrigo A; Casale R; Giorgi I; Guarnaschelli C; Zelaschi F
Curr Med Res Opin; 1989; 11(8):491-500. PubMed ID: 2680286
[TBL] [Abstract][Full Text] [Related]
3. Effects of long-term ergoloid mesylates ('Hydergine') administration in healthy pensioners: 5-year results.
Huber F; Köberle S; Prestele H; Spiegel R
Curr Med Res Opin; 1986; 10(4):256-79. PubMed ID: 3780290
[TBL] [Abstract][Full Text] [Related]
4. Co-dergocrine plasma concentrations and blood pressure changes in hypertensive patients during therapy with slow-release co-dergocrine mesylate.
Woodcock BG; Herrmann W; Habedank WD
Int J Clin Pharmacol Ther Toxicol; 1992 Feb; 30(2):63-5. PubMed ID: 1551748
[TBL] [Abstract][Full Text] [Related]
5. A controlled long-term study with ergoloid mesylates (Hydergine) in healthy, elderly volunteers: results after three years.
Spiegel R; Huber F; Köberle S
J Am Geriatr Soc; 1983 Sep; 31(9):549-55. PubMed ID: 6886282
[TBL] [Abstract][Full Text] [Related]
6. On brain protection of co-dergocrine mesylate (Hydergine) against hypoxic hypoxidosis of different severity: double-blind placebo-controlled quantitative EEG and psychometric studies.
Saletu B; Grünberger J; Anderer R
Int J Clin Pharmacol Ther Toxicol; 1990 Dec; 28(12):510-24. PubMed ID: 2086492
[TBL] [Abstract][Full Text] [Related]
7. Analysis of the cardiovascular effects of co-derocrine (Hydergine).
Clark BJ; Bucher T; Waite R
J Pharmacol; 1985; 16 Suppl 3():101-11. PubMed ID: 2869189
[TBL] [Abstract][Full Text] [Related]
8. [Effect of co-dergocrine mesylate on catecholamines and prolactin in elderly hypertensive patients].
Mies R; Lang R; Weidinger G; Welzel D
Arzneimittelforschung; 1983; 33(5):771-3. PubMed ID: 6683557
[TBL] [Abstract][Full Text] [Related]
9. Effects of Hydergine on platelet deposition on "active" human carotid artery lesions and platelet function.
Steurer G; Fitscha P; Ettl K; Sinzinger H
Thromb Res; 1989 Sep; 55(5):577-89. PubMed ID: 2814944
[TBL] [Abstract][Full Text] [Related]
10. Effects of co-dergocrine mesylate (Hydergine) in multi-infarct dementia as evaluated by positron emission tomography.
Nagasawa H; Kogure K; Kawashima K; Ido T; Itoh M; Hatazawa J
Tohoku J Exp Med; 1990 Nov; 162(3):225-33. PubMed ID: 2091324
[TBL] [Abstract][Full Text] [Related]
11. Psychophysiological research in psychiatry and neuropsychopharmacology. II. The investigation of antihypoxidotic/nootropic drugs (tenilsetam and co-dergocrine-mesylate) in elderlies with the Viennese Psychophysiological Test-System (VPTS).
Saletu B; Semlitsch HV; Anderer P; Resch F; Presslich O; Schuster P
Methods Find Exp Clin Pharmacol; 1989 Jan; 11(1):43-55. PubMed ID: 2716439
[TBL] [Abstract][Full Text] [Related]
12. Assessment of the effect of mirodenafil on the hemodynamics of healthy male Korean volunteers administered tamsulosin: a randomized, double-blind, placebo-controlled, 2-period crossover study.
Gu N; Kim J; Lim KS; Shin KH; Kim TE; Lee B; Shin SG; Jang IJ; Yu KS
Clin Ther; 2012 Sep; 34(9):1929-39. PubMed ID: 22921287
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular regulation during administration of co-dergocrine to normal subjects.
Gerber A; Weidmann P; Laederach K
Eur J Clin Pharmacol; 1986; 29(5):565-72. PubMed ID: 3956562
[TBL] [Abstract][Full Text] [Related]
14. The treatment of asthmatic patients using an alpha-adrenergic receptor blocking agent, co-dergocrine mesylate ('Hydergine').
Kitamura S
Pharmatherapeutica; 1980; 2(5):330-6. PubMed ID: 7433473
[TBL] [Abstract][Full Text] [Related]
15. Dose-response studies with co-dergocrine mesylate under hypoxia utilizing EEG mapping and psychometry.
Saletu B; Grünberger J; Linzmayer L; Anderer P
Psychopharmacology (Berl); 1992; 109(1-2):30-40. PubMed ID: 1365669
[TBL] [Abstract][Full Text] [Related]
16. Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of the effects on blood pressure of abrupt cessation versus taper down of guanfacine extended-release tablets in adults aged 19 to 24 years.
Kisicki JC; Fiske K; Lyne A
Clin Ther; 2007 Sep; 29(9):1967-79. PubMed ID: 18035196
[TBL] [Abstract][Full Text] [Related]
17. Hemodynamic and humoral effects at rest and after head-up tilt tests during 24-hour infusion of a new nitrate ester, ITF 296, compared with ISDN and placebo in healthy volunteers: a double-blind, randomized, within-subject study.
Sardina M; Warrington SJ; Boyce M; Johnston A; Bianchini C
J Cardiovasc Pharmacol; 1995; 26 Suppl 4():S80-90. PubMed ID: 8839231
[TBL] [Abstract][Full Text] [Related]
18. Double blind study of the influence of co-dergocrine on platelet parameters in healthy volunteers.
Sinzinger H
Eur J Clin Pharmacol; 1985; 28(6):713-6. PubMed ID: 2998802
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular regulation and lipoprotein profile during administration of co-dergocrine in essential hypertension.
Uehlinger DE; Weidmann P; Gnaedinger MP
Eur J Clin Pharmacol; 1989; 36(2):119-25. PubMed ID: 2721537
[TBL] [Abstract][Full Text] [Related]
20. Co-dergocrine mesylate inhibits the increase in plasma catecholamines caused by nifedipine in essential hypertension.
Kirsten R; Nelson K; Weidinger G; Welzel D
Eur J Clin Pharmacol; 1990; 39(5):435-9. PubMed ID: 2076734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
